<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000298</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-09260-1</org_study_id>
    <secondary_id>P50-09260-1</secondary_id>
    <nct_id>NCT00000298</nct_id>
  </id_info>
  <brief_title>Buprenorphine Combination Tablet Feasibility - 1</brief_title>
  <official_title>Buprenorphine Combination Tablet Feasibility</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine target dose range of buprenorphine/naloxone
      combination tablet that provides therapeutic response in opiate addicts with low to moderate
      dependence, and to identify appropriate initial induction dose in opiate addicts with low to
      moderate dependence.&quot;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 1995</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Withdrawal symptoms</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Opiate use</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Opiate craving</measure>
  </primary_outcome>
  <enrollment>0</enrollment>
  <condition>Opioid-Related Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine/naloxone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Males/Females ages 21-50, opiate dependence according to DSM-IV criteria, self-reported use
        within the last 30 days, agreeable to conditions of study and signed informed consent

        Exclusion Criteria:

        Psychiatric disorder that requires medication therapy, history of seizures, pregnant and/or
        nursing women, dependence on etoh or benzodiazepines or other sedative-hypnotics, acute
        hepatitis, other medical conditions that deem participation to be unsafe.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Ling, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friends Research Institute, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Friends Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Buprenorphine/nalaxone cmbination tablet: First clinical experience (j. Add Dis 1997, in press). Buprenorphine/naloxone combination tablet: First clincial experience (J Add Dis 1997, in press).</citation>
  </reference>
  <verification_date>January 1996</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 1999</study_first_submitted>
  <study_first_submitted_qc>September 20, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 1999</study_first_posted>
  <last_update_submitted>August 16, 2005</last_update_submitted>
  <last_update_submitted_qc>August 16, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

